Recent Updates
Recently added Catalysts

Envista Holdings Corporation

NVSTFDA catalysts, PDUFA dates & pipeline intelligence
$23.27
▼ -0.48 · -2.02%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full NVST financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $18.7952W HIGH $30.42
Volume
2.45 M
Value Traded
57.02 M
Short % Float
6.21%
Days to Cover
3.0
-5.64%Week
+1.31%1 Month
-13.59%3 Month
-1.52%6 Month
-47.16%5 Year
-8.65%All Time

Cash Data

Unlock NVST cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
3.73 B
EPS (TTM)
3.95
P/E Ratio
5.89
Ent. Value
4.00 B
Total Shares
160.34 M
Float Shares
156.55 M
Insiders
2.36%
Institutions
126.16%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every NVST catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

NVST Catalyst Timeline

Dated clinical, regulatory and corporate events for Envista Holdings Corporation

Unlock the full NVST catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How NVST actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all NVST historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 86%
Small Cap
(rank 622 of 723)
Percentile Rank
Showing 0 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Unlock the NVST pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every NVST program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every NVST trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock NVST insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Reis MischaOfficer (SVP, Strategy & Bus. Dev.)Sell -8,000 27,321 held$27.50 08/20/2026
Unlock the full NVST insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
PARKMAN HEALTHCARE PARTNERS LLC 0.6 % (-60 %) 6.60 M 281.00 K -49.27% ( -272.91 K)
Unlock every fund holding NVST
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in NVST
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see NVST ownership
Insider and institutional ownership, quarter by quarter.

NVST Short Interest

Shares sold short, counted twice a month.

6.21%
Short % of Float
of tradable shares sold short
9.7M
Shares Sold Short
-0.5% vs prior count
3.0 Moderate
Days to Cover
trading days of normal volume to buy every short share back
3.3M
Avg Daily Volume
the average used for days to cover
Unlock NVST short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock NVST option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live NVST option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock NVST options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How NVST ranks across every disease it competes in

Competitive Position is a premium feature
See how NVST ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

NVST News

NVST
Nov 10, 2026
NVSTGeneral

Envista Announces Pricing of $430 Million of Senior Notes

Envista Holdings Corporation announced the pricing of $430 million in Senior Notes due 2033. The offering, priced at 99.482% of the principal amount, is set to close around November 24, 2026. The proceeds will be used to repay a term loan and for general corporate purposes. J.P. Morgan, BofA, and Wells Fargo are the active bookrunners.

Read more →
NVST
Nov 4, 2026
NVSTGeneral
▼ -8.2%on this newsshared move

Envista Reports Third Quarter 2026 Results

Envista Holdings Corporation reported third quarter results for 2026, achieving sales of $691 million with a core sales growth of 2.7% compared to the previous year. The company also reported a GAAP diluted EPS of $3.11 and adjusted EBITDA of $106 million. CEO Paul Keel expressed confidence in raising the full-year earnings guidance due to strong momentum.

Read more →
NVST
Oct 27, 2026
NVSTGeneral

Envista Announces Release of 2025 Sustainability Report

Envista Holdings released its 2025 Sustainability Report, detailing progress in waste reduction and community support. The company cut waste generation by 40% and water consumption by 19% year-over-year. Additionally, the Envista Smile Project donated $2.4 million to serve nearly 20,000 patients. The firm also reported a 17% decrease in lost time injury rates during the period.

Read more →
NVST
Oct 6, 2026
NVSTConferences/Events

Envista Schedules Third Quarter 2026 Earnings Call

Envista Holdings Corporation will announce its third quarter 2026 financial results on November 4, 2026. The results will be discussed during a conference call at 2:00 PM PT, which will be available via webcast. A replay of the call will be accessible for one year. Envista is recognized as a leader in the dental industry with a strong brand portfolio.

Read more →
NVST
Sep 8, 2026
NVSTConferences/Events

Envista Announces Participation in Baird 2026 Global Healthcare Conference

Envista Holdings Corporation announced its participation in the Baird 2026 Global Healthcare Conference, scheduled for September 15, 2026. The event will include a fireside chat from 9:40 to 10:10 AM ET. A live audio webcast will be available on Envista's investor relations website, allowing broader access to stakeholders.

Read more →
NVST
Aug 5, 2026
NVSTGeneral

Envista Reports Second Quarter 2026 Results

Envista Holdings Corporation reported a strong second quarter for 2026, with sales reaching $731 million and a core sales growth of 5% compared to the previous year. The company also saw a significant increase in adjusted diluted EPS, which rose by 58%. CEO Paul Keel highlighted the positive momentum and operational excellence contributing to margin expansion, prompting an upward revision of the full-year outlook for sales growth and adjusted EBITDA.

Read more →
NVST
Jul 28, 2026
NVSTConferences/Events
▲ +5.2%on this news

Envista to Host Investor Day on September 17, 2026

Envista Holdings Corporation has announced an Investor Day scheduled for September 17, 2026. The event will feature a management presentation followed by a Q&A session, allowing investors to engage directly with company leaders. It will be webcast live, with a replay available later. In-person attendance requires prior registration.

Read more →
NVST
Jul 7, 2026
NVSTConferences/Events
▼ -5.1%on this news

Envista Schedules Second Quarter 2026 Earnings Call

Envista Holdings Corporation will announce its second quarter 2026 financial results on August 5, 2026. The discussion will take place during a conference call starting at 2:00 PM PT, which will be accessible via the company's website. A replay of the call will be available for one year, ensuring ongoing access to the information.

Read more →
NVST
May 6, 2026
NVSTGeneral

Envista Reports First Quarter 2026 Results

Envista Holdings Corporation reported strong first quarter results for 2026, achieving a 9.5% core revenue growth and a 50% increase in adjusted EPS compared to the previous year. The company also announced a $300 million share repurchase program, reflecting confidence in its financial performance. However, it faced challenges with negative operating and free cash flows during the quarter.

Read more →
NVST
Apr 8, 2026
NVSTConferences/Events
▲ +5.4%on this news

Envista Schedules First Quarter 2026 Earnings Call

Envista Holdings Corporation will announce its financial results for the first quarter of 2026 on May 6, 2026. The company will host a conference call at 2:00 PM PT to discuss these results, which will be accessible via a webcast. A replay of the call will be available for one year, and relevant materials will be posted on their website.

Read more →
NVST
Feb 5, 2026
NVSTGeneral

Envista Reports Fourth Quarter 2025 Results

Envista Holdings Corporation reported strong financial results for Q4 2025, achieving a 10.8% core revenue growth and a 22% increase in adjusted EBITDA. The company also noted a full-year revenue growth of 6.5% and a significant return of $166 million to shareholders through share repurchases. CEO Paul Keel emphasized the positive performance across all major business segments and regions.

Read more →
NVST
Jan 8, 2026
NVSTConferences/Events

Envista Schedules Fourth Quarter 2025 Earnings Call

Envista Holdings Corporation will announce its fourth quarter 2025 financial results on February 5, 2026. The results will be discussed during a conference call starting at 2:00 PM PT. Investors can access the call via phone or through a webcast on the company's website.

Read more →
NVST
Jan 7, 2026
NVSTConferences/Events

Envista to Present at the 44th Annual J.P. Morgan Healthcare Conference

Envista Holdings Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation is scheduled from 3:45 to 4:25 pm PST and will be available via a live audio webcast. A replay will be accessible for 30 days on the company's website.

Read more →
NVST
Nov 25, 2025
NVSTConferences/Events

Envista Announces Participation in 8th Annual Evercore Healthcare Conference

Envista Holdings Corporation will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025. The event will feature a fireside chat from 12:30 to 1:15 pm ET. A live audio webcast will be accessible on the company's investor relations website.

Read more →
NVST
Oct 29, 2025
NVSTGeneral

Envista Announces Release of 2024 Sustainability Report

Envista Holdings Corporation released its 2024 Sustainability Report, detailing its commitment to sustainable practices. Key highlights include a $1.9 million donation to enhance oral care access and a 13% reduction in safety incidents. CEO Paul Keel emphasized the company's dedication to creating lasting value for stakeholders.

Read more →
NVST
Oct 29, 2025
NVSTGeneral

Envista Reports Third Quarter 2025 Results

Envista Holdings Corporation reported strong Q3 2025 results with $670 million in sales, marking a 9.4% increase from the previous year. Adjusted EPS rose 167% to $0.32, while adjusted EBITDA also saw a significant increase of 77%. Despite a GAAP net loss of $30 million, the company achieved profitability in its Spark aligners business.

Read more →
NVST
Sep 30, 2025
NVSTConferences/Events

Envista Schedules Third Quarter 2025 Earnings Call

Envista Holdings Corporation will announce its third quarter 2025 financial results on October 30, 2025. A conference call will follow at 2:00 PM PT, lasting about one hour. The call will be available via webcast, and a replay will be accessible for one year. Additional materials will be posted on their website.

Read more →
NVST
Jul 31, 2025
NVSTGeneral
▼ -5.4%on this news

Envista Reports Second Quarter 2025 Results

Envista Holdings Corporation reported strong financial results for Q2 2025, with sales reaching $682 million and a core sales growth of 5.6% year-over-year. The company also saw a significant increase in adjusted EBITDA and EPS, prompting an upward revision of its full-year guidance. CEO Paul Keel noted accelerated growth across all business segments.

Read more →
NVST
Jul 9, 2025
NVSTConferences/Events

Envista Schedules Second Quarter 2025 Earnings Call

Envista Holdings Corporation will announce its second quarter 2025 financial results on July 31, 2025. The earnings call will start at 2:00 PM PT and last about one hour. Investors can access the call via phone or through a webcast on the company's website. A replay will be available after the call.

Read more →
NVST
May 22, 2025
NVSTConferences/Events

Envista Announces Participation in Stifel 2025 Jaws & Paws Conference

Envista Holdings Corporation announced its participation in the Stifel 2025 Jaws & Paws Conference. The fireside chat is scheduled for May 28, 2025, from 1:50 to 2:20 pm ET. A live audio webcast will be available on the company's investor relations website.

Read more →

About Envista Holdings Corporation

Brea, CA 12,000 employees envistaco.com
Headquarters200 S. KRAEMER BLVD., BLDG. E, BREA, CA, 92821
BIOPHARMAWATCH ELITE
Trade the next NVST catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime